Figure 4.

Membrane-proximal CD33-targeting chimeric antigen receptor (CAR) T cells provide enhanced survival in xenograft mouse model. (A) Schematic diagram of in vivo experimental setup. NCG mice were inoculated with U937-CD33^high tumor and subsequently treated with CAR T cells. (B) Survival of NCG mice bearing U937-CD33^high tumors and treated with titrated doses of CAR T cells (n=5; **p<0.01, *p<0.05). P values for survival determined by log-rank Mantel-Cox test, with 95% CI. (C) Tumor regression of NCG mice inoculated with U937-CD33^high tumor and subsequently treated with 5.0×10⁵ of CAR T cells. (D) Bioluminescence over time of U937-CD33^high in tumor-bearing NCG mice treated with 5.0×10⁵ CAR T cells. (E) Schematic diagram of in vivo experimental setup. NCG mice were inoculated with OCiAML3-CD33^low tumor and subsequently treated with CAR T cells. (F) Survival of NCG mice inoculated with OCiAML3-CD33^low tumors and treated with 5.0×10⁵ CAR T cells (n=5; *p<0.05). P values for survival determined by log-rank Mantel-Cox test, with 95% CI. (G) Tumor regression of NCG mice bearing OCiAML3-CD33^low tumors and treated with 5.0×10⁵ CAR T cells. (H) Bioluminescence over time of OCiAML3-CD33^low in tumor-bearing NCG mice treated with 5.0×10⁵ CAR T cells.